The Watertown, Massachusetts, company said eravacycline proved to be not inferior to a competing drug, ertapenem, and patients taking it had no serious, drug-related side effects, according to early results from the study.
The grants awarded by the Colorado Board of Health will go to studies on whether marijuana helps...
Earlier this week, President Barack Obama signed into law a little piece of legislation that may...
United Therapeutics Corporation has announced two senior executive promotions as well as changes to Martine Rothblatt, Ph.D's compensation program.
Halozyme Therapeutics has entered into a worldwide collaboration and license agreement with Janssen Biotech for the purpose of developing and commercializing products combining proprietary Janssen compounds with Halozyme's ENHANZE technology.
Napster co-founder Sean Parker says he missed most of his final year in high school and has ended up in the emergency room countless of times because of his deadly allergy to nuts, shellfish and other foods.
The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development (R&D) in 2013, an increase of $723 million over the previous year, according to research and consulting firm GlobalData.
Lilly has been dealing with a drop in both earnings and revenue due to the loss of patents protecting key drugs from cheaper generic competition. Company executives have said they remained committed to the dividend, despite the financial blows the company was absorbing, but some analysts have questioned whether that commitment might waver.
U.S. District Judge Robert Sweet told Dublin-based Actavis PLC to continue making the drug Namenda available for 30 days after generic alternatives become available on July 11 "in order to allow for an orderly transition."
A wave of corporate mega deal activity drove a significant uptick in M&A value in 2014, according to PwC US. As businesses aim to meet their growth ambitions and increase market share, PwC expects there will be more attractive opportunities for dealmakers to acquire, combine and align with strategic partners in 2015.
New York's attorney general says a drug manufacturer has been ordered to halt plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.
Under the terms of the agreement, OPKO will receive an upfront payment of $295M and is eligible to receive up to an additional $275M upon the achievement of certain regulatory milestones. Pfizer will receive the exclusive license to commercialize hGH-CTP worldwide.
Philadelphia's Transportation Authority has filed a lawsuit against Gilead Sciences over the pricing of its hepatitis C drug. Gilead has been selling a 12-week treatment of Sovaldi in the United States for approximately $84,000, or $1,000 per pill.
Nearly 20 percent of U.S. consumers, 42.9 million people, have unpaid medical debts, according to a new report by the Consumer Financial Protection Bureau. The findings suggest that many Americans are being trapped by debt because they are confused by the notices they get from hospitals and insurance companies about the cost of treatment.
Pharmaceutical companies will suffer an estimated $65B drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData. The company’s report states that the drug makers hit hardest will include Otsuka, Eli Lilly, and AstraZeneca, with a significant proportion of losses coming in the Central Nervous System treatment sector.
With 288 deals and $95.2b raised, 2014 will end with record activity in the US IPO markets, according to the EY Global IPO Trends: 2014 Q4 report released today. While 2013 saw a revival of IPOs in the US, 2014 was even more exceptional. As of December, the number of listings was at its highest point since 2000 and is a 27% increase over 2013.
Ed Price, President of PCI Synthesis, issues his annual list of trends that he feels will continue to affect the emerging biotech and generic drug industries in 2015.
With 104 programs in late-stage clinical development, the stem cell therapy space could reach the commercialization threshold by 2017, but a number of challenges remain, according to research and consulting firm GlobalData.
Merck remains committed to its $8.4 billion acquisition of Cubist Pharmaceuticals even though a federal court invalidated most of the company's patents protecting its top-selling antibiotic just hours after the deal was announced this week.
The debt-financed acquisition of Cubist Pharmaceuticals by Merck for $9.5 billion is the latest in a string of large, debt-financed acquisitions that are stressing the credit profiles of US healthcare companies, according to Fitch Ratings.
Natrol has announced the completion of the sale of substantially all of the company’s assets to Aurobindo Pharma USA Inc., a manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, for a purchase price of $132.5M plus assumed liabilities.
Sigma-Aldrich Corporation stockholders voted to adopt the previously announced merger agreement providing for the acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany at a special meeting of stockholders.
Puerto Rico's governor says Florida-based pharmaceutical company Romark Laboratories is building a $110M plant in the U.S. territory. Alejandro Garcia Padilla says construction will begin in January and that nearly 200 jobs will be created in three years.
Dynavax Technologies and AstraZeneca signed an amendment to the existing Research Collaboration and License Agreement under which AstraZeneca will fully fund and Dynavax will conduct a Phase 2a safety and efficacy trial of AZD1419 in patients with asthma.
Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating genetic diseases, has entered into a global collaboration with Pfizer for the development and potential commercialization of SPK-FIX, a development program advancing proprietary, bio-engineered adeno-associated virus vectors for the potential treatment of hemophilia B.
Merck is buying Cubist Pharmaceuticals for $8.4 billion, illustrating a new emphasis on combating so-called "superbugs" that are drawing dire warnings from global health organizations.
In its annual Top Health Industry Issues of 2015 report, PwC’s Health Research Institute (HRI) anticipates that the $2.8 trillion U.S. healthcare sector will start feeling like a true market. HRI’s report explores the top 10 trends that are expected to shape the sector in 2015
Meda, a Recipharm’s customer, announced that they will transfer supply of their mainly Swedish penicillin products and manufacture offshore with other suppliers. The manufacturing contract with Recipharm Strängnäs will therefore be terminated as of December 31, 2015.
- Page 1